The desired features of pharmaceutical drug delivery systems (DDS) for parenteral (itravenous)administration include their small size, biodegradability, high content of a drug in a final preparation,prolonged circulation in the blood, and, ideally, the ability to target required areas passively (via theenhanced permeability and retention-EPR-effect) or actively (via specific ligands, such as monoclonalantibodies). While these requirements are reasonably well met by a variety of DDS (liposomes,microcapsules, nanoparticles) for water-soluble drugs, the development of nanoparticulate DDSdisplaying all of these properties for poorly soluble pharmaceuticals still represents a challenge.'Low solubility in water, however, tends to be an intrinsic property of many drugs, including powerfulanti-cancer agents. This is not surprising, since the membrane permeability and efficacy of variousdrugs increase with increasing hydrophobicity.At the same time, intravenous administration of those
The desired features of pharmaceutical drug delivery systems (DDS) for parenteral (itravenous)administration include their small size, biodegradability, high content of a drug in a final preparation,prolonged circulation in the blood, and, ideally, the ability to target required areas passively (via theenhanced permeability and retention-EPR-effect) or actively (via specific ligands, such as monoclonalantibodies). While these requirements are reasonably well met by a variety of DDS (liposomes,microcapsules, nanoparticles) for water-soluble drugs, the development of nanoparticulate DDSdisplaying all of these properties for poorly soluble pharmaceuticals still represents a challenge.'Low solubility in water, however, tends to be an intrinsic property of many drugs, including powerfulanti-cancer agents. This is not surprising, since the membrane permeability and efficacy of variousdrugs increase with increasing hydrophobicity.At the same time, intravenous administration of those
正在翻译中..